



Five Prime Therapeutics, Inc.  
Investor Relations Department  
Two Corporate Dr, Suite 200  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: FPRX <sup>1</sup>

Last Trade:	46.23
Trade Time:	2:18 PM ET Tuesday, October 17, 2017
Change:	-0.51 (1.091%)
Day Range	46.14 - 48.21
52-Week Range	25.97 - 60.98
Volume	411,356
Market Cap. (\$M)	1,336.047
Shares Out (M)	28.900

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Wednesday, October 11, 2017*  
[Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer \(SITC\) 32nd Annual Meeting](#)

*Thursday, September 21, 2017*  
[Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology](#)

*Sunday, September 10, 2017*  
[Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress](#)

*Sunday, September 10, 2017*  
[Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress](#)

*Friday, September 1, 2017*  
[Five Prime Announces Abstract with Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

*Friday, February 24, 2017*  
[Annual Report \(10-K\)](#)

*Friday, March 31, 2017*  
[Definitive Proxy Statement](#)

*Tuesday, August 8, 2017*  
[Quarterly Report \(10-Q\)](#)

*Friday, May 5, 2017*  
[Quarterly Report \(10-Q\)](#)

*Friday, November 4, 2016*  
[Quarterly Report \(10-Q\)](#)